SG178919A1 - Sustituted ( heteroarylmethyl ) thiohydantoins as anticancer drugs - Google Patents

Sustituted ( heteroarylmethyl ) thiohydantoins as anticancer drugs

Info

Publication number
SG178919A1
SG178919A1 SG2012014262A SG2012014262A SG178919A1 SG 178919 A1 SG178919 A1 SG 178919A1 SG 2012014262 A SG2012014262 A SG 2012014262A SG 2012014262 A SG2012014262 A SG 2012014262A SG 178919 A1 SG178919 A1 SG 178919A1
Authority
SG
Singapore
Prior art keywords
heteroarylmethyl
thiohydantoins
sustituted
anticancer drugs
prophylaxis
Prior art date
Application number
SG2012014262A
Other languages
English (en)
Inventor
Ulrich Luecking
Arwed Cleve
Bernard Haendler
Gimenez Hortensia Faus
Silke Koehr
Horst Irlbacher
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of SG178919A1 publication Critical patent/SG178919A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SG2012014262A 2009-09-11 2010-08-28 Sustituted ( heteroarylmethyl ) thiohydantoins as anticancer drugs SG178919A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09075421 2009-09-11
EP10075069 2010-02-17
PCT/EP2010/005297 WO2011029537A1 (en) 2009-09-11 2010-08-28 Sustituted ( heteroarylmethyl ) thiohydantoins as anticancer drugs

Publications (1)

Publication Number Publication Date
SG178919A1 true SG178919A1 (en) 2012-04-27

Family

ID=42782041

Family Applications (1)

Application Number Title Priority Date Filing Date
SG2012014262A SG178919A1 (en) 2009-09-11 2010-08-28 Sustituted ( heteroarylmethyl ) thiohydantoins as anticancer drugs

Country Status (28)

Country Link
US (1) US20120251551A1 (OSRAM)
EP (1) EP2475653A1 (OSRAM)
JP (1) JP2013504523A (OSRAM)
KR (1) KR20120065396A (OSRAM)
CN (1) CN102639523A (OSRAM)
AR (1) AR078166A1 (OSRAM)
AU (1) AU2010294588A1 (OSRAM)
BR (1) BR112012005526A2 (OSRAM)
CA (1) CA2773591A1 (OSRAM)
CL (1) CL2012000623A1 (OSRAM)
CO (1) CO6511228A2 (OSRAM)
CR (1) CR20120113A (OSRAM)
CU (1) CU20120042A7 (OSRAM)
DO (1) DOP2012000063A (OSRAM)
EA (1) EA201200473A1 (OSRAM)
EC (1) ECSP12011716A (OSRAM)
IL (1) IL218390A0 (OSRAM)
IN (1) IN2012DN02081A (OSRAM)
MA (1) MA33566B1 (OSRAM)
MX (1) MX2012002977A (OSRAM)
NZ (1) NZ598643A (OSRAM)
PE (1) PE20121180A1 (OSRAM)
PH (1) PH12012500497A1 (OSRAM)
SG (1) SG178919A1 (OSRAM)
TN (1) TN2012000108A1 (OSRAM)
TW (1) TW201111378A (OSRAM)
UY (1) UY32882A (OSRAM)
WO (1) WO2011029537A1 (OSRAM)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2540728T1 (sl) 2010-02-17 2019-06-28 Takeda Pharmaceutical Company Limited Heterociklična spojina
EP2576536B1 (en) * 2010-06-01 2016-09-14 The University of Queensland Haematopoietic-prostaglandin d2 synthase inhibitors
EA035493B1 (ru) 2011-12-22 2020-06-25 Янссен Байофарма, Инк. Замещенные нуклеозиды, нуклеотиды и их аналоги
USRE48171E1 (en) 2012-03-21 2020-08-25 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
US9441007B2 (en) 2012-03-21 2016-09-13 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
AP3545A (en) 2012-05-25 2016-01-14 Janssen Sciences Ireland Uc Uracyl spirooxetane nucleosides
TW201418243A (zh) 2012-11-15 2014-05-16 Bayer Pharma AG 含有磺醯亞胺基團之n-(吡啶-2-基)嘧啶-4-胺衍生物
AP2015008533A0 (en) 2012-12-21 2015-06-30 Alios Biopharma Inc Substituted nucleosides, nucleotides and analogs thereof
WO2014153280A1 (en) * 2013-03-22 2014-09-25 Merck Sharp & Dohme Corp. 2-pyridyl carboxamide-containing spleen tyrosine kinase (syk) inhibitors
CN104341351B (zh) * 2013-07-30 2018-02-06 北京海美源医药科技有限公司 一种二芳基硫代乙内酰脲衍生物及其应用
DK3080100T3 (da) * 2013-12-11 2023-02-06 Celgene Quanticel Res Inc Hæmmere af lysinspecifik demethylase-1
CN105829296A (zh) 2013-12-18 2016-08-03 巴斯夫欧洲公司 带有亚胺衍生的取代基的唑类化合物
US9682960B2 (en) 2013-12-19 2017-06-20 Endorecherche, Inc. Non-steroidal antiandrogens and selective androgen receptor modulators with a pyridyl moiety
CN103896847B (zh) * 2014-04-09 2016-01-20 沈江 一种非甾体类抗雄激素化合物及其制备方法和应用
AU2015257917C1 (en) 2014-05-07 2019-03-14 Evotec International Gmbh Sulfoximine substituted quinazolines for pharmaceutical compositions
TWI656121B (zh) 2014-08-04 2019-04-11 德商拜耳製藥公司 2-(嗎啉-4-基)-1,7-萘啶
CN106187905B (zh) * 2015-05-05 2020-02-21 北京海步医药科技股份有限公司 丁鲁他胺的结晶形式及其制备方法
EP3359544B1 (en) 2015-10-08 2020-08-12 Bayer Pharma Aktiengesellschaft Novel modified macrocyclic compounds
WO2017060322A2 (en) 2015-10-10 2017-04-13 Bayer Pharma Aktiengesellschaft Ptefb-inhibitor-adc
TWI726969B (zh) 2016-01-11 2021-05-11 比利時商健生藥品公司 用作雄性激素受體拮抗劑之經取代之硫尿囊素衍生物
EP3601236A1 (en) 2017-03-28 2020-02-05 Bayer Aktiengesellschaft Novel ptefb inhibiting macrocyclic compounds
EP3601253B1 (en) 2017-03-28 2021-09-15 Bayer Aktiengesellschaft Novel ptefb inhibiting macrocyclic compounds
EP3625215B1 (en) 2017-05-18 2023-09-13 PI Industries Ltd Formimidamidine compounds useful against phytopathogenic microorganisms
WO2019158517A1 (en) 2018-02-13 2019-08-22 Bayer Aktiengesellschaft Use of 5-fluoro-4-(4-fluoro-2-methoxyphenyl)-n-{4-[(s-methylsulfonimidoyl)methyl]pyridin-2-yl}pyridin-2-amine for treating diffuse large b-cell lymphoma
WO2020209933A1 (en) * 2019-04-11 2020-10-15 University Of Miami Improved inhibitors of the notch transcriptional activation complex and methods for use of the same
WO2021150603A1 (en) * 2020-01-21 2021-07-29 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Aryl hydantoin heterocycles and methods of use
CN117120436A (zh) * 2021-03-30 2023-11-24 苏州开拓药业股份有限公司 一种一步法合成乙内酰硫脲衍生物的方法
WO2025103470A1 (zh) * 2023-11-17 2025-05-22 中国药科大学 作为雄激素受体(ar)拮抗剂的化合物及其应用
CN120309588B (zh) * 2025-06-10 2025-08-12 上海健康医学院 一种具有雄激素受体和组蛋白去乙酰化酶6双重抑制作用的乙内酰硫脲类化合物及其用途

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE35956E (en) 1991-01-09 1998-11-10 Roussel Uclaf Phenylimidazolidines having antiandrogenic activity
US5411981A (en) 1991-01-09 1995-05-02 Roussel Uclaf Phenylimidazolidines having antiandrogenic activity
FR2693461B1 (fr) 1992-07-08 1994-09-02 Roussel Uclaf Nouvelles phénylimidazolidines substituées, leur procédé de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant.
FR2671348B1 (fr) 1991-01-09 1993-03-26 Roussel Uclaf Nouvelles phenylimidazolidines, leur procede de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant.
FR2694290B1 (fr) 1992-07-08 1994-09-02 Roussel Uclaf Nouvelles phénylimidazolidines éventuellement substituées, leur procédé de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant.
TW521073B (en) 1994-01-05 2003-02-21 Hoechst Marion Roussel Inc New optionally substituted phenylimidazolidines, their preparation process, their use as anti-androgenic agent and the pharmaceutical compositions containing them
FR2716110B1 (fr) 1994-02-16 1996-04-05 Roussel Uclaf Compositions cosmétiques ou pharmaceutiques comprenant des liposomes.
US5656651A (en) 1995-06-16 1997-08-12 Biophysica Inc. Androgenic directed compositions
EP1122242B1 (en) 1998-09-22 2008-01-16 Astellas Pharma Inc. Cyanophenyl derivatives
US6472415B1 (en) 1998-12-18 2002-10-29 Biophysica, Inc. Androgen receptor suppressors in the therapy and diagnosis of prostate cancer, alopecia and other hyper-androgenic syndromes
US6861432B2 (en) 2001-11-23 2005-03-01 Schering Aktiengesellschaft Piperazine derivatives that destabilize androgen receptors
MXPA04009960A (es) 2002-04-12 2004-12-13 Pfizer Compuestos de pirazol como agentes anti-inflamatorios y analgesicos.
US20060247286A1 (en) 2003-07-02 2006-11-02 Milton Hammond Oxazolidinone antibiotics and derivatives thereof
KR20060097024A (ko) 2003-09-30 2006-09-13 얀센 파마슈티카 엔.브이. 벤조이미다졸 화합물
EP1706385B1 (en) 2003-12-23 2010-10-06 Astex Therapeutics Limited Pyrazole derivatives as protein kinase modulators
TW200612920A (en) 2004-08-03 2006-05-01 Chugai Pharmaceutical Co Ltd Novel imidazolidine derivatives
KR20070106969A (ko) 2004-09-09 2007-11-06 추가이 세이야쿠 가부시키가이샤 신규 이미다졸리딘 유도체 및 그 용도
DE602005021150D1 (de) 2004-12-03 2010-06-17 Hoffmann La Roche 3-substituierte pyridinderivate als h3-antagonisten
RU2448096C3 (ru) * 2005-05-13 2017-12-11 Те Риджентс Оф Те Юниверсити Оф Калифорния Диарилгидантоины
US7709516B2 (en) 2005-06-17 2010-05-04 Endorecherche, Inc. Helix 12 directed non-steroidal antiandrogens
RU2449993C2 (ru) 2006-03-29 2012-05-10 Те Риджентс Оф Те Юниверсити Оф Калифорния Диарилтиогидантоиновые соединения
AR069039A1 (es) 2007-10-26 2009-12-23 Univ California Compuestos de diarilhidantoina, composicion farmaceutica, proceso de obtencion del compuesto, utiles para desordenes hiperproliferativos
WO2009097995A1 (de) * 2008-02-07 2009-08-13 Sanofi-Aventis Neue phenyl-substituierte imidazolidine, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung

Also Published As

Publication number Publication date
CL2012000623A1 (es) 2012-09-14
CO6511228A2 (es) 2012-08-31
NZ598643A (en) 2013-10-25
UY32882A (es) 2011-04-29
CU20120042A7 (es) 2012-06-21
DOP2012000063A (es) 2012-05-15
IN2012DN02081A (OSRAM) 2015-08-21
IL218390A0 (en) 2012-04-30
JP2013504523A (ja) 2013-02-07
US20120251551A1 (en) 2012-10-04
PH12012500497A1 (en) 2012-10-22
EP2475653A1 (en) 2012-07-18
EA201200473A1 (ru) 2012-10-30
CR20120113A (es) 2012-05-02
BR112012005526A2 (pt) 2016-04-26
PE20121180A1 (es) 2012-08-24
MX2012002977A (es) 2012-04-30
KR20120065396A (ko) 2012-06-20
AU2010294588A1 (en) 2012-04-05
CN102639523A (zh) 2012-08-15
CA2773591A1 (en) 2011-03-17
WO2011029537A1 (en) 2011-03-17
TW201111378A (en) 2011-04-01
MA33566B1 (fr) 2012-09-01
ECSP12011716A (es) 2012-04-30
AR078166A1 (es) 2011-10-19
TN2012000108A1 (en) 2013-09-19

Similar Documents

Publication Publication Date Title
TN2012000108A1 (en) Sustituted (heteroarylmethyl) thiohydantoins as anticancer drugs
MY185666A (en) Anticancer pyridopyrazines via the inhibition of fgfr kinases
MX356205B (es) Benzopirazinas anticancerigenas via la inhibicion de cinasas del receptor del factor de crecimiento de fibroblasto (fgfr).
PH12012501993A1 (en) Pyrazolyl quinazoline kinase ihibitors
CA2871471C (en) Dna-pk inhibitors
WO2012088266A3 (en) Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
MX346147B (es) Compuestos de 3-aril-5-substituido-isoquinolin-1-ona y su uso terapeutico.
MX2015006152A (es) Compuestos de aminopirimidina como inhibidores de mutantes de egfr que contienen t7 9 0m.
MY157124A (en) Substituted imidazopyridinyl-aminopyridine compounds
PH12012501337A1 (en) Substituted pyrrolo-aminopyrimidine compounds
MX342250B (es) Tratamiento de cánceres resistentes a antagonistas notch1, mediante el uso de antagonistas notch3.
MX366899B (es) Nuevos compuestos.
IN2012DN02471A (OSRAM)
PH12012501556A1 (en) Substituted naphthalenyl-pyrimidine compounds
CA2865983A1 (en) Potent anticancer activity via dual compound activation
MX2011006532A (es) Compuestos anticancerigenos.
GB2519004A (en) Quinone compounds and their uses for the treatment of cancer
MX2012007471A (es) Compuestos substituidos de pirrolo-aminopirimidina.